{
    "2019-08-29": [
        [
            {
                "time": "",
                "original_text": "【安信非银】复星国际中报点评：聚焦产业运营显效，盈利稳中有升",
                "features": {
                    "keywords": [
                        "复星国际",
                        "中报",
                        "产业运营",
                        "盈利"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "投资"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "毛利率相差近10个百分点，康龙化成冲刺H股，对标药明康德有多大压力？",
                "features": {
                    "keywords": [
                        "毛利率",
                        "康龙化成",
                        "H股",
                        "药明康德"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "复宏汉霖赴港上市再进一步 复星医药新药研发进入回报期？",
                "features": {
                    "keywords": [
                        "复宏汉霖",
                        "赴港上市",
                        "复星医药",
                        "新药研发",
                        "回报期"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "复星医药：费用上升研发多投 待新药上市改善业绩",
                "features": {
                    "keywords": [
                        "复星医药",
                        "费用上升",
                        "研发投入",
                        "新药上市",
                        "业绩改善"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "@基民们，大家心目中的“硬核科技”基金有哪些？",
                "features": {
                    "keywords": [
                        "硬核科技",
                        "基金"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "基金"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "BioBAY香港子公司成立 充分参与全球创新",
                "features": {
                    "keywords": [
                        "BioBAY",
                        "香港子公司",
                        "全球创新"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物科技",
                        "创新"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星国际上半年收入涨57% 郭广昌：复星的定位是消费产业集团 不是多元化投资企业",
                "features": {
                    "keywords": [
                        "复星国际",
                        "收入增长",
                        "郭广昌",
                        "消费产业集团",
                        "多元化投资"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "消费",
                        "投资"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}